1. Home
  2. IMSR vs RLMD Comparison

IMSR vs RLMD Comparison

Compare IMSR & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terrestrial Energy Inc.

IMSR

Terrestrial Energy Inc.

N/A

Current Price

$2.17

Market Cap

400.4M

Sector

N/A

ML Signal

N/A

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

N/A

Current Price

$2.66

Market Cap

348.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMSR
RLMD
Founded
2013
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
400.4M
348.8M
IPO Year
2024
2012

Fundamental Metrics

Financial Performance
Metric
IMSR
RLMD
Price
$2.17
$2.66
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$9.88
★ $10.75
AVG Volume (30 Days)
★ 2.0M
1.8M
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 45.28
EPS
★ N/A
N/A
Revenue
★ $248,357.00
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$2.25
$2.84
52 Week High
$13.53
$8.00

Technical Indicators

Market Signals
Indicator
IMSR
RLMD
Relative Strength Index (RSI) 31.45 35.26
Support Level N/A N/A
Resistance Level $3.65 $4.73
Average True Range (ATR) 0.26 0.44
MACD -0.02 -0.14
Stochastic Oscillator 0.00 2.18

Price Performance

Historical Comparison
IMSR
RLMD

About IMSR Terrestrial Energy Inc.

Terrestrial Energy Inc develops Generation IV nuclear power plants based on its proprietary Integral Molten Salt Reactor (IMSR) technology. Its small modular reactor plants are designed to provide low-carbon electricity and high-temperature industrial heat for applications including power generation, petrochemical and chemical processing, and data centers. The company is working with regulators, suppliers, industrial partners, and energy users to develop, license, and commission IMSR plants.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: